Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation
Academic Article
Publication Date:
2021
Short description:
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation / Perez-Valero, I., Llibre, J.M., Castagna, A., Pulido, F., Molina, J., Esser, S., Margot, N., Shao, Y., Temme, L., Piontkowsky, D., Mcnicholl, I.R., Haubrich, R.. - In: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. - ISSN 1525-4135. - 86:4(2021), pp. 490-495. [Epub ahead of print] [10.1097/QAI.0000000000002595]
abstract:
The ability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) to maintain virologic suppression in participants with M184V and/or M184I resistance mutations from historical genotypic reports when switching from a tenofovir disoproxil fumarate (TDF)- or abacavir (ABC)-based regimen was investigated.
Iris type:
1.1 Articolo in rivista
List of contributors:
Perez-Valero, Ignacio; Llibre, Josep M; Castagna, Antonella; Pulido, Federico; Molina, Jean-Michel; Esser, Stefan; Margot, Nicolas; Shao, Yongwu; Temme, Lauren; Piontkowsky, David; Mcnicholl, Ian R; Haubrich, Richard
Published in: